Status:
COMPLETED
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
Lead Sponsor:
Sun Pharmaceutical Industries Limited
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
Detailed Description
This is a Phase II, randomized, double-blind, placebo-controlled study to determine the effect of SCD-044 in subjects with moderate to severe atopic dermatitis.
Eligibility Criteria
Inclusion
- Aged at least 18 years.
- Males and non-pregnant non-lactating females, diagnosed with chronic atopic dermatitis for ≥ 1 year at Screening and Baseline based on Eichenfield revised criteria of Hanifin and Rajka.
- Moderate to severe atopic dermatitis at Screening and Baseline
Exclusion
- Female Subjects who are pregnant, nursing, or planning to become pregnant during study participation or within 6 months of completing the study.
- Known organ complications of Diabetes mellitus such as reduced renal function, significant retinal pathology or neuropathy.
- History or presence of uveitis
- \-
Key Trial Info
Start Date :
July 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04684485
Start Date
July 30 2021
End Date
March 18 2025
Last Update
December 30 2025
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Omni Dermatology
Phoenix, Arizona, United States, 85018
2
Yuma Clinical Trials, LLC
Yuma, Arizona, United States, 85364
3
T. Joseph Raoof Md, Imc./Encino Research Center
Encino, California, United States, 91436
4
Metropolis Dermatology
Los Angeles, California, United States, 90017